Yes. Management could make a deal tomorrow for ten bucks. Of course what they are doing is satisfying BP expectations for clinical results that justify a deal whose terms create shareholder value. This means terms that reflect the likely commercial value for each of our pipeline drugs, and that ain't ten bucks. It's also not "TEN BILLION DOLLARS!!!", for reasons explained by experienced investors here.
We've reached that point for B. In the next two months we'll reach that point for P and K, too. This is an exciting time. Hopefully lucrative too.
News 
Market Data 
Discover 
